Please login to the form below

Not currently logged in
Email:
Password:

umeclidinium

This page shows the latest umeclidinium news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

GSK has high hopes for three-drug combination Trelegy (fluticasone furoate/umeclidinium/vilanterol), but with third-quarter sales of £42m, that is still a long way off its blockbuster sales projections.

Latest news

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    triple – based on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate – in the US and Europe last year. ... pitted it against GSK’s two-drug LAMA/LABA Anoro (umeclidinium/vilanterol).

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    Bevespi demonstrated non-inferiority to GSK’s Anoro (umeclidinium/vilanterol) on peak forced expiratory volume in one second (FEV1) but did not demonstrate superiority on peak FEV1 or non-inferiority on ... GSK’s Trelegy (umeclidinium/vilanterol/

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    The new US label means Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) can be used in a broader population of chronic obstructive pulmonary disease (COPD) patients with difficulty breathing or who see ... GSK claims Trelegy has made the

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate - in the US and Europe last year.

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The EU regulator cleared Trelegy (fluticasone furoate/umeclidinium/vilanterol) - considered to be the most important new product in the company’s ailing respiratory franchise - as a maintenance treatment in adults with ... GSK has been bringing other

More from news
Approximately 9 fully matching, plus 52 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics